Numbers

The Numbers

Lee & Man Chemical trades at HK$4.85 for roughly HK$4.1B of market cap, 7.3x trailing earnings, 0.64x book, 5.4x EV/EBITDA and a 7.0% dividend yield — the screen of a tired Chinese commodity chemical. But the underlying engine earns through-cycle ROE in the mid-teens, converts 80%+ of net income to free cash in good years, and carries the lightest balance sheet in its peer group (net debt / equity 0.06, net debt / EBITDA 0.4x). The stock is re-rating off the FY2023 trough on margin recovery, not volume growth. The single number that will re-rate or de-rate the share price from here is the ECU gross margin — 34.5% in FY2025 vs a 26.2% trough and a 47% peak — and whether trend-line coal and chlor-alkali ASPs let that number hold.

What this company is, in numbers

Three-plant chlor-alkali operation at steady volume, margins that swing on ECU pricing, capex that has stayed at roughly 2x depreciation for a decade as the Jiangxi and Zhuhai sites scaled up, and a balance sheet that barely flexes. Revenue is up only 29% over 11 years (FY2014 HK$1.56B to FY2025 HK$3.75B, about 2.4% CAGR) while net income has swung between HK$216M (FY2016) and HK$1.29B (FY2021). This is textbook commodity cyclical.

The margin triad is the real story. Gross margin has traded in a 26% to 47% band for 15 years with no trend, because it is set by ECU pricing (caustic plus chlorine derivatives) net of coal and brine costs. The 2017-18 and 2021 peaks both coincided with Chinese supply-side shocks that pulled competing chlor-alkali capacity offline; the 2023 trough was a simultaneous collapse of caustic ASP (around 26% YoY) and chloromethane ASP (31-50%) against sticky coal. FY2025's 34.5% gross margin is sitting almost exactly on the 20-year median.

Half-year cadence — the recent direction

The most decision-relevant time series is half-year, not annual: 0746 reports semi-annually, and the spread between 1H and 2H inside each fiscal year tells you whether raw-material costs or end-demand is leading.

The direction readers must internalise: gross margin peaked in 1H25 at 36.3% and gave back to 32.6% in 2H25. Consensus is modelling continued margin expansion through FY2026; the company's own most recent half-year print says that is not yet happening. This is the single biggest short-term watch item.

Is it healthy? Cash conversion is the answer

The reported earnings are real. Over FY2015-FY2025 the company generated HK$10.7B of operating cash flow against HK$6.4B of reported net income — an average OCF/NI of 1.68x, which for a manufacturer is strong (depreciation adds back, working capital releases in downturns). Conversion to free cash is lumpier because capex has run at HK$500-770M for a decade as Jiangxi fluoropolymer and Zhuhai FEC capacity was built.

Trailing-5y FCF/NI is 58% — on the light side of healthy, pulled down by capex that did not ease in the 2023 trough. This is the uncomfortable truth in the numbers: every HK$1 of reported profit is converting to about 60 cents of free cash, not because of accrual games but because the capex line keeps reinvesting into new lines (Jiangxi high-end fluoropolymer, Changshu vinyl chloride, Zhuhai FEC). If you are valuing the dividend stream and assuming capex normalises to 1x depreciation, you are implicitly assuming those projects have finished spending — and FY2025 capex of HK$512M against depreciation of HK$90M says they have not.

Capital allocation — dividend cut and rebuild

Zero buybacks in 20 years. The dividend was cut 44% in FY2023 (from HK31c to HK17c per share) as FCF collapsed and has been rebuilding since (HK27c in FY2024, HK34c in FY2025). Management has been explicit that capex funding takes priority, which is correct given the return profile of the base business and the absence of an M&A pipeline. The net effect: cumulative FY2017-2025 capex of HK$5.5B against cumulative FCF of HK$3.6B, with the HK$1.9B gap funded by a mix of retained high-margin vintages and modest rolling debt.

Balance sheet — the cleanest in the peer set

Quality scorecard

Top-quartile Quality Score (86) driven by profitability and balance sheet. The catch is Predictability of 1 out of 5 — this is exactly what you would expect of a commodity producer with 3x peak-to-trough earnings swings. Do not size this like a staple.

Valuation — the single most important chart

The multiples tell a consistent story: 0746 is trading right at its 20-year median on EV/EBITDA (5.4x vs 6.1x) and slightly above its 10-year average on P/E (7.3x vs 6.1x). It is not cheap on its own history, and it is not expensive either. What is cheap is the P/B at 0.64x against a 20-year median of 1.65x — but that reads through more as a reminder that ROE is running at 8.8% (below the 10y average closer to 15%) than as a standalone value signal. The right way to read valuation: the re-rate from the 2023 trough (HK$2.97) to today (HK$4.85, up over 60%) has already recaptured most of the margin mean-reversion. You are now paying mid-cycle multiples for mid-cycle earnings.

Peers — earnings quality vs the cohort

Four of the six listed peers posted GAAP losses in FY2025. Of the profitable three (0746, Tosoh, Lee & Man Paper), 0746 has the lowest leverage by a wide margin and the highest gross margin. That is the peer-gap that matters: Tosoh earns its premium multiple from specialty-electronic-materials diversification; 0746 earns its margins from the captive-demand and low-cost-power combination Warren's note described. The market is pricing 0746 broadly in line with paper-sister 2314 on EV/EBITDA and well inside Olin/Dow on P/E — a reasonable place to be given the earnings-quality gap runs the other way.

Fair value — three anchors, one range

Three independent methods, each deliberately simple.

Method A — 20y median EV/EBITDA times normalised EBITDA. Through-cycle EBITDA around HK$1.0B (average of 10y HK$1.05B and 5y HK$1.07B, haircut for capex intensity) at 6.1x equals HK$6.1B EV. Less HK$351M net debt equals HK$5.75B equity value. At 838M shares, that is HK$6.86 per share.

Method B — Dividend yield reversion. FY2025 dividend HK$0.34, 20y median yield 6.0%. Implied price equals HK$0.34 divided by 0.060 equals HK$5.67 per share.

Method C — Fair Value estimate (external, 12m forward). HK$3.64 per share — materially below current price of HK$4.85.

What the numbers confirm, contradict, and what to watch

The numbers confirm that this is a high-quality commodity cyclical, not a specialty company — mid-teens ROE through cycle, 80%+ cash conversion peak-to-trough, and a balance sheet that lets it run full-load through the bad years instead of cutting production like its leveraged peers. The numbers contradict the screen-level read that 0746 is a cheap Chinese chemical: at 7.3x P/E on recovering earnings, 5.4x EV/EBITDA against a 6.1x 20-year median, and 0.64x book against 8.8% ROE, it is trading at mid-cycle multiples on what is already a mid-cycle earnings print. The 2H25 re-tracement in gross margin (36.3% to 32.6%) says the re-rate has run ahead of the fundamentals. Watch three things through FY2026: caustic soda and chloromethane ASP trends (the single P&L driver); the FY2026 capex line — if it drops from HK$512M back toward HK$300M, FCF conversion jumps overnight and the payout can step up materially; and the dividend cover — a third straight year of stable payout on recovering earnings would reset the yield floor and act as the technical re-rate catalyst the balance sheet has already earned.